Chiricozzi A, Maurelli M, Gori N, et al. - Researchers conducted this retrospective, multicenter study to characterize dupilumab effectiveness and tolerability in treating adult individuals with chronic nodular prurigo (CNPG) refractory to both topical and systemic therapies. Participants in the study were adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks. In terms of skin lesions, itch, sleeplessness, and quality of life, 27 CNPG patients exhibited clinical improvement. Ten patients have completed 36 weeks of continuous care ensuring clinical efficacy. Dupilumab has been shown to be effective in reducing itch and improving skin lesions caused by CPNG.